NcXHF

KREM AND GOPAL
References
1. Coiffıer B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab
compared with CHOP alone in elderly patients with diffuse large-B-cell
lymphoma. N Engl J Med. 2002;346:235-242.
2. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to
fludarabine and cyclophosphamide in patients with chronic lymphocytic
leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;
376:1164-1174.
3. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared
with cyclophosphamide, vincristine, and prednisone alone in
patients with previously untreated advanced follicular lymphoma. J Clin
Oncol. 2008;26:4579-4586. Epub 2008 Jul 28.
4. Herold M, Haas A, Srock S, et al. Rituximab added to fırst-line mitoxantrone,
chlorambucil, and prednisolone chemotherapy followed
by interferon maintenance prolongs survival in patients with advanced
follicular lymphoma: an East German Study Group Hematology
and Oncology Study. J Clin Oncol. 2007;25:1986-1992. Epub
2007 Apr 9.
5. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy
and interferon in follicular lymphoma patients: results of the
GELA-GOELAMS FL2000 study. Blood. 2008;112:4824-4831.
6. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with
rituximab added to the combination of cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP) signifıcantly improves the outcome
for patients with advanced-stage follicular lymphoma compared
with therapy with CHOP alone: results of a prospective randomized
study of the German Low-Grade Lymphoma Study Group. Blood. 2005;
106:3725-3732. Epub 2005 Aug 25.
7. Byrd JC, Jones JJ, Woyach JA, et al. Entering the era of targeted therapy
for chronic lymphocytic leukemia: impact on the practicing clinician.
J Clin Oncol. 2014;32:3039-3047.
8. Merli M, Ferrario A, Basilico C, et al. Novel agents in indolent lymphomas.
Ther Adv Hematol. 2013;4:133-148.
9. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classifıcation
of lymphoid neoplasms and beyond: evolving concepts and practical
applications. Blood. 2011;117:5019-5032.
10. García-Sanz R, Montoto S, Torrequebrada A, et al. Waldenström macroglobulinaemia:
presenting features and outcome in a series with 217
cases. Br J Haematol. 2001;115:575-582.
11. Seng JE, Peterson BA. Indolent B-cell non-Hodgkin’s lymphomas. Oncology.
1997;11:1883-1894, 1987; discussion 1901-1902, 1.
12. Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy
by sub-type: a report from the Haematological Malignancy Research
Network. Br J Cancer. 2011;105:1684-1692.
13. Sharman JP, Mato A, Kay NE, et al. Demographics by age group (AG)
and line of therapy (LOT) in chronic lymphocytic leukemia (CLL) patients
(Pts) treated in US practices from the Connect CLL registry. Paper
presented at: 56th Annual ASH Meeting and Exposition; December
2014; San Francisco, CA.
14. Wildes TM, Goede V, Hamlin P. Personalizing therapy for older adults
with lymphoid malignancies: options and obstacles. Am Soc Clin Oncol
Educ Book. 2014;e240-248.
15. Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its
potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-
174.
16. Kuijpers TW, Bende RJ, Baars PA, et al. CD20 defıciency in humans
results in impaired T cell-independent antibody responses. J Clin Invest.
2010;120:214-222.
17. Johnson P, Glennie M. The mechanisms of action of rituximab in the
elimination of tumor cells. Semin Oncol. 2003;30 (1 Suppl 2):3-8.
18. Maloney DG. Concepts in radiotherapy and immunotherapy: anti-
CD20 mechanisms of action and targets. Semin Oncol. 2005;32:S19-
S26.
19. Desai AV, El-Bakkar H, Abdul-Hay M. Novel agents in the treatment of
chronic lymphocytic leukemia: a review about the future. Clin Lymphoma
Myeloma Leuk. Epub 2014 Sep 30.
20. van Oers MH. CD20 antibodies: type II to tango? Blood. 2012;119:5061-
5063.
21. Samaniego F, Berkova Z, Romaguera JE, et al. 90Y-ibritumomab
tiuxetan radiotherapy as fırst-line therapy for early stage low-grade
B-cell lymphomas, including bulky disease. Br J Haematol. 2014;167:
207-213.
22. Ibatici A, Pica GM, Nati S, et al. Safety and effıcacy of (90) yttriumibritumomab-tiuxetan
for untreated follicular lymphoma patients. An
Italian cooperative study. Br J Haematol. 2014;164:710-716.
23. Morschhauser F, Radford J, Van Hoof A, et al. 90Yttrium-ibritumomab
tiuxetan consolidation of fırst remission in advanced-stage follicular
non-Hodgkin lymphoma: updated results after a median follow-up of
7.3 years from the International, Randomized, Phase III First-Line Indolent
trial. J Clin Oncol. 2013;31:1977-1983.
24. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent
CD20 immunotherapy in fludarabine-refractory chronic lymphocytic
leukemia. J Clin Oncol. 2010;28:1749-1755.
25. Hillmen P, Robak T, Janssens A, et al. Ofatumumab chlorambucil
versus chlorambucil alone in patients with untreated chronic lymphocytic
leukemia (CLL): results of the phase III study Complement 1
(OMB110911). Paper presented at: 55th Annual ASH Meeting and Exposition;
December 2013; New Orleans, LA.
26. Herring W, Pearson I, Purser M, et al. Cost-effectiveness of ofatumumab
plus chlorambucil in fırst line chronic lymphocytic leukemia in
Canada. Value Health. 2014;17:A633.
27. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in
patients with CLL and coexisting conditions. N Engl J Med. 2014;370:
1101-1110.
28. Veenstra DL, Reyes CM, Ramsey SD. Is obinutuzumab cost-effective in
the fırst-line treatment of CLL? Paper presented at: 2014 ASCO Annual
Meeting; June 2014; Chicago, IL.
29. Gray N. “NICE rejects funding for Roche’s leukemia drug.” BioPharma
Dive, October 3, 2014. http://www.biopharmadive.com. Accessed December
15, 2014.
30. McKee S. “NICE ‘no’ for Roche’s Gazyvaro in CLL.” PharmaTimes, October
3, 2014. http://www.pharmatimes.com. Accessed December 28,
2014.
31. Masangkay EG. “NICE set to recommend Roche’s Gazyvaro for CLL.”
Outsourced Pharma, December 9, 2014. http://www.outsourcedpharma.com.
Accessed December 28, 2014.
32. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges
and limitations. Nat Rev Cancer. 2009;9:550-562.
33. Westin JR. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.
Clin Lymph Myeloma Leuk. 2014;14:335-342. Epub 2014 Feb 7.
34. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on
a theme. Oncogene. 2008;27:5497-5510.
35. Gopal AK, Kahl BS, de Vos S, et al. PI3K inhibition by idelalisib in
patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:
1008-1018.
36. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in
relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997-
1007.
37. Flinn I, Oki Y, Patel M, et al. a Phase 1 evaluation of duvelisib (IPI-145),
e372
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook